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Introduction: Crohn’s disease (CD) is characterized by chronic and relapsing
inflammation of the gastro-intestinal tract. It is assumed that oxidative stress contributes
to CD pathogenesis, but systemic biomarkers for oxidative stress in CD are not yet
identified. A reduction in free thiol groups in plasma proteins (“plasma free thiols”) reflects
systemic oxidative stress since they are prime substrates for reactive oxygen species.
Here, we determined the concentrations of plasma free thiols in CD patients and healthy
controls and studied the putative correlation with disease parameters.
Methods: Free thiols were quantified in plasma of patients with CD in clinical remission
[according to the Harvey Bradshaw Index (HBI)] and healthy controls and adjusted
for plasma albumin. Albumin-adjusted free thiol concentrations were analyzed for
associations with clinical and biochemical disease markers.
Results: Mean plasma free thiol concentrations were significantly lower in patients with
CD (n = 51) compared to healthy controls (n = 27) (14.7 ± 2.4 vs. 17.9 ± 1.8 µmol/g
albumin; P < 0.001). Patients with CD with above-average free thiols had significantly
lower CRP levels (median 1.4 [interquartile range] [0.4; 2.6] vs. 3.6 [0.6; 7.0] mg/L;
P < 0.05) and BMI (23.6± 4.8 vs. 27.1± 5.2 kg/m2; P < 0.05). Patients with CD having
solely colonic disease demonstrated markedly reduced plasma free thiol concentrations
compared to patients with ileocolonic involvement (13.2 ± 1.8 vs. 15.2 ± 2.2 µmol/g;
P < 0.05). Finally, plasma free thiol concentrations negatively correlated with biomarkers
of inflammation, including hsCRP, SAA, IL-17A (all P < 0.05), and VEGF.
Conclusion: Plasma free thiols are reduced in patients with CD in clinical remission
compared to healthy controls. Thus, subclinical CD disease activity is reflected by
systemic oxidative stress and plasma free thiols may be a relevant therapeutic target
and biomarker to monitor disease activity in CD.
Keywords: Crohn’s disease, free thiols, oxidative stress, redox status, disease activity, biomarker
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INTRODUCTION
Crohn’s disease (CD) is an inflammatory bowel disease (IBD)
characterized by chronic transmural intestinal inflammation that
can affect any part of the gastro-intestinal tract (Sartor, 2008).
Most patients follow a disease course of alternating exacerbations
and remissions, which are difficult to predict and adequately
treat (Cosnes et al., 2011). CD has a complex, multifactorial
origin, eventually leading to an inappropriate and uncontrolled
immune response with impaired gut mucosal homeostasis
(Fiocchi, 1998; Abraham and Cho, 2009). At the mucosal
level, IBD is characterized by chronic infiltration of various
activated inflammatory cells, including polymorphonuclear
cells, eosinophils and plasma cells (Kruidenier and Verspaget,
2002). Besides, even in clinical remission, subclinical intestinal
inflammation is present in a large proportion of CD patients
(Cosnes et al., 2011).
Oxidative stress has been implicated to play a pivotal role
in CD pathogenesis, and may be a key effector mechanism
leading to cellular/molecular damage and tissue injury (Pereira
et al., 2015; Guan and Lan, 2018). Oxidative stress is
characterized by increased production of reactive oxygen species
(ROS). Accumulating evidence indicates that chronic intestinal
inflammation in IBD is intimately associated with increased
systemic levels of oxidative stress and enhanced ROS production,
however, this evidence is predominantly derived from tissue
analysis (Keshavarzian et al., 1992; Tanida et al., 2011; Zhu and
Li, 2012; Pereira et al., 2015). Furthermore, plasma and mucosal
antioxidant defense components that are necessary to neutralize
ROS are significantly decreased in CD (D’Odorico et al., 2001;
Kruidenier et al., 2003; Koutroubakis et al., 2004; Hengstermann
et al., 2008). Therefore, the combination of excess ROS
production and diminished antioxidant capacity might explain
several pathophysiological aspects of CD (Alzoghaibi, 2013).
Plasma free thiols (R-SH, sulfhydryl groups) are generally
considered as a robust measure of the overall in vivo reduction-
oxidation (redox) status. Thiol groups are rapidly oxidized by
reactive oxygen metabolites, thus systemic oxidative stress is
associated with reduced plasma free thiol levels (Banne et al.,
2003). Extracellularly, reduced free thiols are present in very low
concentrations and the percentage of oxidized thiols is higher as
compared to the intracellular environment (Turell et al., 2013).
In plasma of healthy individuals, thiols predominantly occur
as protein-embedded cysteine residues (Go and Jones, 2011).
Circulating albumin harbors the largest pool of plasma free
thiol groups, of which roughly 75% is present in the reduced
state in healthy conditions (Hortin et al., 2008). Furthermore,
low molecular weight (LMW) thiols, though scarcely present in
the extracellular compartment, mainly circulate complexed with
albumin (Turell et al., 2013). High concentrations of plasma free
thiols, as potent antioxidants, are thus representative of a more
favorable redox status in vivo.
Although plasma free thiols may pose a reliable reflection
of systemic oxidative stress, concentrations of plasma free thiol
groups have not yet been evaluated in IBD, nor in CD specifically.
Similarly, to the best of our knowledge, the potential role of
plasma free thiols as biomarker for intestinal health has not
been addressed before. In contrast, the role of free thiols has
been examined in a variety of other (inflammatory) disease
conditions, including cardiovascular disease (CVD), type 2
diabetes, and renal failure (Banne et al., 2003; Kundi et al.,
2015; Frenay et al., 2016; Koning et al., 2016; Cortese-Krott
et al., 2017). In other studies, decreased plasma free thiols
were associated with cardiovascular risk factors, including aging,
elevated body-mass index (BMI), and alcohol consumption
(Go and Jones, 2011; Khalili et al., 2015). Conversely, elevated
concentrations of plasma free thiol groups were strongly
associated with favorable CVD outcome (Frenay et al., 2016;
Koning et al., 2016).
Learning more about the systemic redox status, as reflected
by plasma free thiols, is imperative since plasma free thiols have
potent antioxidant activity and might serve as a therapeutic target
(Dröge, 2002). Furthermore, CD patients with latent disease who
show signs of systemic oxidative stress might have increased
susceptibility to disease exacerbations. Therefore, determination
of plasma free thiol concentrations and analyzing their
associations with clinical and biochemical disease parameters
might provide valuable information regarding the extent of
systemic oxidative stress in CD in remission. In the present
study, we hypothesized that plasma concentrations of free thiol
groups (R-SH) are decreased in CD patients as compared to
healthy controls and negatively correlate with inflammatory
biomarkers. In addition, we aimed to identify associations




This study is an exploratory analysis from a study cohort
that has previously been described elsewhere (Bourgonje et al.,
2018). From March 2016 to April 2017, 51 patients with
an established diagnosis of CD were included at the IBD
outpatient clinic of the University Medical Center Groningen
(UMCG), Groningen, Netherlands. All patients were ≥18 years
of age and had an established diagnosis of CD existing for
at least 1 year. Diagnosis was based on clinical, endoscopic
and histopathological criteria (Lennard-Jones, 1989). At time
of inclusion, most patients were in clinical remission and 39
of 51 (76.5%) patients were treated with conventional IBD
therapy (i.e., thiopurines, mesalamine, TNF-antagonists or a
combination of these drugs). The study was approved by the
Institutional Review Board (IRB) of the UMCG (in Dutch:
“Medisch Ethische Toetsingscommissie”) (IRB No. 14/291).
All patients provided written informed consent in accordance
with the Declaration of Helsinki (2013). Blood samples were
obtained after patients provided written informed consent. In
addition, plasma samples of 27 healthy, non-IBD controls were
included for comparison, which were retrieved from a UMCG
biobank containing pre-donation samples of living kidney donors
[PSI-UMCG (IRB No. 08/279)]. Plasma samples from CD
patients and non-IBD controls were obtained according to
the same protocol.
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Data Collection
Demographic characteristics of all participants were registered,
including age, sex, body-mass index (BMI, body weight divided
by squared height), and smoking behavior. For the CD cohort,
further disease-specific clinical characteristics were recorded,
including the Montreal classification, maintenance medication
(thiopurines, mesalamine, TNF-antagonists, or combination
therapy), surgical history, and the Harvey-Bradshaw Index
(HBI) as clinical disease activity index (Harvey and Bradshaw,
1980). Disease location according to the Montreal classification
was recorded from the most recently performed endoscopic
evaluation, which was completed at least within 12 months
of serum analysis. CD patients with upper gastrointestinal
disease or active perianal disease were not included in the
study. Routine laboratory measurements were performed in
all study participants, including hemoglobin (Hb), C-reactive
protein (CRP), erythrocyte sedimentation rate (ESR), white
blood cell count (WBC), platelet count, albumin, aspartate
transaminase (AST), alanine transaminase (ALT), and creatinine
(Roche Modular, Roche, Mannheim, Germany). The estimated
glomerular filtration rate (eGFR) was calculated using the
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation (Levey et al., 2009). In CD patients, fecal calprotectin
levels were measured by enzyme-linked immunosorbent assays
(ELISA) (BÜHLMANN Laboratories AG, Switzerland) as routine
measurement in the UMCG.
Measurement of Plasma Free Thiols
Plasma samples were stored at −80◦C until measurement
of free thiols. Plasma free thiol groups were measured as
previously described, with minor modifications (Ellman, 1959;
Hu et al., 1993). Firstly, samples were 4-fold diluted with
0.1 M Tris buffer (pH 8.2). After transfer to a microplate,
background absorption was measured at 412 nm with a reference
measurement at 630 nm using a Varioskan plate reader (Thermo
Fisher Scientific, Breda, Netherlands). After adding 20 µL
1.9 mM 5,5′-dithio-bis (2-nitrobenzoic acid) (DTNB, Ellman’s
Reagent, CAS-number 69-78-3, Sigma-Aldrich Corporation, St.
Louis, MO, United States) in phosphate buffer (0.1 M, pH 7.0),
following an incubation time of 20 min at room temperature,
free thiol groups were colorimetrically detected through a second
sample absorbance measurement. Final free thiol concentrations
were determined by parallel measurement of a L-cysteine
(CAS-number 52-90-4, Fluka Biochemika, Buchs, Switzerland)
calibration curve with a concentration range from 15.6 µM
to 1,000 µM in 0.1 M Tris/10 mM EDTA (pH 8.2). Plasma
free thiol concentrations were corrected for plasma albumin by
dividing the concentrations, since albumin is the most abundant
human plasma protein, and is the predominant source of thiols
(Turell et al., 2013).
Measurement of Inflammatory
Biomarkers
Measurements of serum concentrations of inflammatory
biomarkers of CD patients were performed as previously
described (Bourgonje et al., 2018). In short, serum samples
from all CD patients were collected and stored in 1 mL aliquots
at −80◦C. After thawing, samples were centrifuged for 3 min
at 2,000 × g to remove remaining particulates. Measurement
of serum levels of high-sensitive C-reactive protein (hsCRP),
serum amyloid A (SAA), IL-17A, and VEGF was performed
using a customized electrochemiluminescence (ECL) multiplex
assay [Meso Scale Discovery (MSD) R©, Meso Scale Diagnostics,
Rockville, MD, United States]. ECL signals were fitted to a
4-parameter logistic model with 1/y2 weighting, ensuring a
broad range of molecule detection. Serum concentrations of all
detected molecules were determined by using calibration curves
to which the ECL signals were back-fitted. Final concentrations
were calculated using the MSD Discovery Workbench analysis
software R©. All concentrations were above the lower limit of
detection (LLOD).
Statistical Analysis
Baseline demographic and clinical characteristics were presented
as means ± standard deviation (SD) or proportions n with
corresponding percentages (%). Non-normally distributed
data were presented as medians [interquartile range (IQR)].
Assessment of normality of continuous variables was performed
using histograms, normal probability plots (Q-Q plots) and
the D’Agostino and Pearson omnibus K2 normality test
(D’Agostino and Pearson, 1973). Between-group comparisons
for continuous variables were performed using independent
sample t-tests or Mann–Whitney U-tests, while for categorical
variables chi-square tests or Fisher’s exact tests were used, as
appropriate. CD patients were subdivided into two groups of
below- and above-average albumin-adjusted plasma free thiol
concentrations and were compared for clinical and laboratory
parameters. Subsequently, univariable and multivariable linear
regression analyses were performed to identify parameters
that were independently associated with albumin-adjusted
plasma free thiols. Multivariable linear regression analysis was
performed using backward selection (Pout > 0.05), including
all significantly associated variables from the univariable
analysis. Skewed variables were logarithmically transformed
before entry into linear regression. Differences between
disease locations according to the Montreal classification were
statistically compared using the non-parametric Kruskal–Wallis
test. Correlations between inflammatory biomarkers and
albumin-adjusted plasma free thiols were established using the
non-parametric Spearman’s correlation coefficient (ρ). Where
appropriate, Bonferroni corrections were applied to correct for
multiple testing. All data were analyzed using SPSS Statistics
23.0 software package (SPSS Inc., Chicago, IL, United States)
and visualized using GraphPad Prism 5.0 (GraphPad Software,




Demographic and clinical characteristics of CD patients (n = 51)
and healthy controls (HC) (n = 27) are presented in Table 1.
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TABLE 1 | Baseline characteristics of Crohn’s disease patients (CD) and healthy controls (HC).
Variables HC CD P-value
n = 27 n = 51
Plasma free thiols per gram of albumin (µmol/g) 17.9 ± 1.8 14.7 ± 2.4 < 0.001
Age (years) 51.2 ± 8.6 42.2 ± 12.2 < 0.001
Female, n (%) 17 (63.0) 38 (74.5) 0.29
BMI (kg/m2) 26.4 ± 3.3 25.5 ± 5.3 0.32
Current smoking, n (%) 7 (25.9) 6 (11.8) 0.11
Laboratory measurements
Hemoglobin (g/dL) 14.5 ± 1.3 13.5 ± 1.3 0.001
CRP (mg/L)∗ 1.1 [0.6; 1.5] 1.8 [0.6; 4.2] 0.16
ESR (mm/h)∗ 3 [2; 4] 14 [7; 27] < 0.001
WBC ( × 109/L)∗ 6.6 [5.0; 8.3] 6.6 [5.4; 7.9] 0.73
Platelets ( × 109/L)∗ 239 [198; 303] 290 [246; 321] 0.02
Albumin (g/L) 45.6 ± 2.7 43.7 ± 2.7 0.003
AST (U/L) 20 ± 4 22 ± 8 0.18
ALT (U/L)∗ 20 [17; 21] 20 [12; 23] 0.89
eGFR (mL/min × 1.73 m2) 89 ± 12 100 ± 14 < 0.001
Creatinine (µmol/l) 78.4 ± 15.8 69.7 ± 10.5 0.005
Data are presented as mean ± SD or proportions (n, %). ∗Skewed data are presented as median [interquartile range]. P-values were two-tailed and calculated using
independent sample t-tests or Mann–Whitney U-tests, as appropriate. Significances are indicated in bold. CD, Crohn’s disease; HC, healthy controls; BMI, body mass
index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell count; AST, aspartate transaminase; ALT, alanine transaminase; eGFR,
estimated glomerular filtration rate.
CD patients had a significantly lower mean age as compared to
healthy controls (42.2 ± 12.2 vs. 51.2 ± 8.6 years), while no
significant gender differences were observed (74.5% vs. 63.0%
females). Furthermore, differences between CD and HC were
observed for several laboratory parameters: CD patients had
significantly lower levels of hemoglobin (P = 0.001), albumin
(P = 0.003), and creatinine (P = 0.005), whereas ESR (P < 0.001),
platelet counts (P = 0.02) and eGFR (P< 0.001) were significantly
increased compared to HC.
Distributions of Albumin-Adjusted
Plasma Free Thiols
In both CD and HC, plasma free thiol (R-SH) concentrations
were normally distributed (D’Agostino and Pearson omnibus K2
normality tests, P = 0.53 and P = 0.52, respectively). Albumin-
adjusted plasma free thiols were significantly reduced in CD as
compared to HC (with a mean of 14.7 ± 2.4 µmol/g for CD
vs. 17.9 ± 1.8 µmol/g for HC, P < 0.001) (Figure 1). After
adjustment for significantly different variables from Table 1,
the difference in albumin-adjusted plasma free thiols remained
statistically significant (P < 0.001).
Further baseline characteristics of the CD patient group are
presented in Table 2, divided by the average concentration of
albumin-adjusted plasma free thiols. CD patients with below-
average albumin-adjusted plasma free thiols (<14.7 µmol/g)
demonstrated significant differences for blood CRP levels and
BMI, as compared to patients with above-average plasma free
thiols per gram of albumin. Patients with below-average albumin-
adjusted plasma free thiols had significantly increased CRP levels
[3.6 (0.6; 7.0) vs. 1.4 (0.4; 2.6) mg/L, P < 0.05] and a significantly
higher BMI (27.1 ± 5.2 vs. 23.6 ± 4.8 kg/m2, P < 0.05).
No significant differences were observed for other documented
FIGURE 1 | Albumin-adjusted plasma free thiols (µmol/g) are highly
significantly reduced in Crohn’s disease (CD) patients compared to healthy
controls (HC) (∗P < 0.001).
variables. Clinical disease activity, as measured with the HBI, was
not significantly different between patients with below- or above-
average plasma free thiols. In the total CD cohort, median HBI
score was 3 [1; 5], indicating that most patients had no active
disease, based on these subjective disease activity scores.
Associations of Albumin-Adjusted
Plasma Free Thiols With Disease
Parameters
Univariable linear regression analyses confirmed that only blood
CRP levels and BMI were significantly associated with albumin-
adjusted plasma free thiol concentrations. Multivariable linear
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TABLE 2 | Baseline demographic, clinical and CD-specific characteristics compared between above- and below-average albumin-adjusted plasma free thiol
concentrations (average: 14.7 ± 2.4 µmol/g).
Variables Total CD cohort Below-average thiols Above-average thiols P-value
n = 51 n = 27 n = 24
Plasma free thiols per gram of albumin (µmol/g) 14.7 ± 2.4 12.9 ± 1.6 16.8 ± 1.3 < 0.001
Age (years) 42.2 ± 12.2 42.2 ± 11.7 42.3 ± 13.0 0.98
Female, n (%) 38 (74.5) 20 (74.1) 18 (75.0) 0.94
BMI (kg/m2) 25.5 ± 5.3 27.1 ± 5.2 23.6 ± 4.8 0.02
Current smoking, n (%) 6 (11.8) 5 (18.5) 1 (4.2) 0.11
Prior surgery, n (%) 19 (37.3) 9 (33.3) 10 (41.7) 0.54
HBI score∗ 3 [1; 5] 3 [1; 5] 3 [2; 5] 0.52
Disease location, n (%) 0.28
L1 (ileal) 17 (33.3) 9 (33.3) 8 (33.3)
L2 (colonic) 11 (21.6) 8 (29.6) 3 (12.5)
L3 (ileocolonic) 23 (45.1) 10 (37.0) 13 (54.2)
Medication, n (%) 0.57
None 12 (23.5) 6 (22.2) 6 (25.0)
Thiopurines 8 (15.7) 6 (22.2) 7 (29.2)
Mesalamine 13 (25.5) 6 (22.2) 2 (8.3)
TNF-antagonists 12 (23.5) 7 (25.9) 5 (20.8)
Combination 6 (11.8) 2 (7.4) 4 (16.7)
Laboratory measurements
Hemoglobin (g/dL) 13.5 ± 1.3 13.5 ± 1.1 13.3 ± 1.5 0.71
CRP (mg/L)∗ 1.8 [0.6; 4.2] 3.6 [0.6; 7.0] 1.4 [0.4; 2.6] 0.04
ESR (mm/h)∗ 14 [7; 27] 17 [7; 27] 13 [6; 20] 0.36
WBC ( × 109/L)∗ 6.6 [5.4; 7.9] 6.6 [5.2; 7.9] 6.9 [5.5; 7.9] 0.56
Platelets ( × 109/L)∗ 290 [246; 321] 298 [252; 361] 275 [242; 311] 0.07
Albumin (g/L) 43.7 ± 2.7 43.7 ± 3.1 43.6 ± 2.2 0.92
AST (U/L) 22 ± 8 21 ± 5 24 ± 9 0.08
ALT (U/L)∗ 16 [12; 23] 16 [14; 22] 16 [10; 27] 0.56
eGFR (mL/min × 1.73 m2) 100 ± 14 99 ± 15 101 ± 13 0.67
Creatinine (µmol/L) 69.7 ± 10.5 70.4 ± 8.8 68.8 ± 12.2 0.60
Fecal calprotectin (µg/g)∗ 140 [42; 358] 74 [40; 325] 160 [74; 359] 0.08
Data are presented as mean ± SD or proportions (n, %). ∗Skewed data are presented as median [interquartile range]. P-values were two-tailed and calculated using
independent sample t-tests or Mann-Whitney U-tests, as appropriate. P-values < 0.05 were considered statistically significant. Significances are indicated in bold. CD,
Crohn’s disease; BMI, body mass index; HBI, Harvey-Bradshaw Index; TNF, tumor necrosis factor; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; WBC,
white blood cell count; AST, aspartate transaminase; ALT, alanine transaminase; eGFR, estimated glomerular filtration rate.
regression analysis showed that only BMI was independently
associated with albumin-adjusted free thiols (Table 3).
Furthermore, we observed an overall significant difference
in albumin-adjusted plasma free thiols between different CD
disease locations according to the Montreal classification
(P < 0.05) (Figure 2). CD patients with solely colonic
disease demonstrated significantly reduced plasma free thiol
concentrations as compared to patients with ileocolonic disease
(13.2 ± 1.8 µmol/g vs. 15.2 ± 2.2 µmol/g, P < 0.05). Patients
with only ileal involvement (15.1 ± 2.8 µmol/g) showed
concentrations comparable with patients having ileocolonic
disease, but no significantly higher concentrations compared to
patients with solely colonic CD.
Albumin-adjusted plasma free thiol concentrations
significantly negatively correlated with several inflammatory
biomarkers in CD (Figure 3). Among these, the strongest
association was observed between albumin-adjusted plasma
free thiols and high-sensitive C-reactive protein (hsCRP)
(ρ = −0.452, P = 0.004) (Figure 3A). Additional significant
correlations were demonstrated for serum amyloid A (SAA)
(ρ = −0.334, P = 0.04) (Figure 3B) and interleukin-17A (IL-
17A) levels (ρ = −0.367, P = 0.02) (Figure 3C). Serum levels
of vascular endothelial growth factor (VEGF) also negatively
correlated with albumin-adjusted plasma free thiols, though
non-significantly (ρ =−0.241, P = 0.15) (Figure 3D).
DISCUSSION
In this study, we demonstrated that albumin-adjusted plasma
free thiol concentrations are significantly decreased in CD in
clinical remission as compared to healthy individuals. In the
CD cohort, we found albumin-adjusted plasma free thiols to
be inversely associated with CRP and BMI, i.e., patients with
beneficial (above-average) concentrations of albumin-adjusted
plasma free thiols had significantly lower CRP and lower
BMI levels. The association with favorable disease status was
further confirmed by the significantly negative correlations
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TABLE 3 | Univariable and multivariable linear regression analyses of
albumin-adjusted plasma R-SH in CD with clinical and biochemical parameters.
Plasma R-SH/gram
of albumin
Univariable analysis Multivariable analysis
Variables B coefficient# P-value B coefficient# P-value
Age −0.091 0.52
Female −0.044 0.76
Current smoker −0.099 0.49
BMI −0.345 0.01† −0.337 0.02†


















Fecal calprotectin∗ 0.241 0.10
∗Skewed data have been logarithmically transformed before entry into analyses.
#Standardized beta (β) coefficient. †P-values < 0.05 were considered statistically
significant. Significances are indicated in bold. R-SH, free thiols; BMI, body mass
index; HBI, Harvey Bradshaw Index; TNF, tumor necrosis factor; CRP, C-reactive
protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell count; AST,
aspartate transaminase; ALT, alanine transaminase; eGFR, estimated glomerular
filtration rate.
FIGURE 2 | Albumin-adjusted plasma free thiols (µmol/g) are most
prominently reduced in CD patients having solely colonic disease (colonic vs.
ileocolonic CD, ∗P < 0.05), according to the Montreal classification of
disease localization.
between plasma free thiol concentrations and the inflammatory
biomarkers hsCRP, SAA, and IL-17A, and non-significantly
with VEGF. Furthermore, we observed that CD patients with
only colonic disease had significantly lower albumin-adjusted
plasma free thiol concentrations as compared to patients with
ileocolonic disease.
This is the first study to investigate the concentrations of
plasma free thiols in a well-described cohort of CD patients
in clinical remission. Our study was sufficiently powered to
be able to detect a significant difference in albumin-adjusted
plasma free thiols between CD and healthy individuals, even after
adjustment for possible confounding factors. Furthermore, the
observed reduction of plasma free thiol concentrations in these
patients becomes an even more remarkable result when taking
into account that most CD patients in this study had a normal
HBI, indicating clinical remission.
In CD, an uncontrolled and persisting inflammatory
response with disturbed intestinal homeostasis is pathologically
represented by abundantly present inflammatory cells in the
intestinal mucosa. Inflammation is intimately linked to oxidative
stress, since the production and release of ROS by the various
inflammatory cells is directly coupled to their immunological
functions (Pereira et al., 2015). Furthermore, active intestinal
inflammation in CD is characterized by increased vascular
density and pathological tissue hypoxia, that may lead to
increased ROS production through activation of targets of
the hypoxia-inducible factor (HIF) transcription factor family
(Biddlestone et al., 2015; Cummins and Crean, 2017). As
such, the inflamed mucosa in CD is constantly exposed to
the harmful effects of oxidative substances, eventually leading
to extensive cell and tissue damage, as is characteristic for
the disease. Oxidative stress is therefore considered to be
one of the key effector mechanisms in CD pathogenesis and
has been linked with many of its manifestations (D’Odorico
et al., 2001; Taha et al., 2010; Alzoghaibi, 2013; Pereira et al.,
2015). Additionally, ROS production by many different
immune cells has been suggested to already occur before
their infiltration into the intestinal mucosa, which is further
substantiating their possible role in disease development
(Beltrán et al., 2010). Moreover, this might partially explain
the systemic concentrations of plasma free thiols as detected in
the present study.
The plasma thiol signaling network has been subject
to investigation in several other diseases, including CVD,
acute and chronic renal failure, diabetes mellitus, familial
hypercholesterolemia, and rheumatoid arthritis (Banne et al.,
2003; Giustarini et al., 2005; Wlodek et al., 2006; Kundi et al.,
2015; Qian et al., 2015; Ates et al., 2016; Koning et al., 2016;
Cortese-Krott et al., 2017; Otal et al., 2018; Simsek et al.,
2018). In all these studies, significant disturbances of the
plasma thiol/disulfide balance were reported, with increased
oxidized thiol forms (disulfides) and decreased free thiols, as
compared to healthy subjects. Furthermore, the total plasma
free thiol pool has been shown to be inversely related to
age and cardiovascular risk factors (Jones et al., 2002; Go
and Jones, 2011). This indicates that the differences we found
may even be an underestimation, since our control group was
slightly older. Additionally, in previous studies, serum free thiols
have demonstrated to be significantly associated with favorable
disease status and better prognosis, for example in CVD,
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FIGURE 3 | Serum levels of (A) high-sensitive CRP (hsCRP), (B) serum amyloid A (SAA), (C) interleukin-17A (IL-17A), and (D) vascular endothelial growth factor
(VEGF) correlate with albumin-adjusted plasma free thiols (µmol/g).
liver failure, neurodegenerative diseases, and renal transplant
recipients (RTRs) (Oettl et al., 2008; McBean et al., 2015; Frenay
et al., 2016; Koning et al., 2016).
Extracellular antioxidant defense components available
to counteract reactive species significantly differ from those
found intracellularly, which mainly consist of the well-
established antioxidant enzymes glutathione peroxidase
(GSH), superoxide dismutase (SOD), and catalase (CAT). In
human plasma, thiol-based plasma proteins predominate as
major source of protection against oxidative stress, next to
the common low molecular weight antioxidants including
uric acid, ascorbic acid (vitamin C), and α-tocopherol
(vitamin E) (Halliwell and Gutteridge, 1990; Motchnik
et al., 1994; Turell et al., 2013). Albumin thiols are the
most abundant thiols in human plasma (accounting for
approximately 75% of the total thiol pool) and oxidized forms
of albumin have been associated with many disease conditions
(Anraku et al., 2013; Turell et al., 2013). Therefore, in the
present study, we adjusted total free thiol concentrations to
plasma albumin levels, which may more accurately represent
systemic redox status.
This study is of particular importance since plasma thiols may
be therapeutically targeted through the exogenous administration
of thiol antioxidants (Deneke, 2000; Atkuri et al., 2007;
Cortese-Krott et al., 2017). Various thiol antioxidants, such
as N-acetylcysteine (NAC), GSH and other derivatives, have
been proposed as treatment for restoring impaired thiol redox
status in both animals and humans. For instance, NAC
supplementation is known to lead to increased extracellular
reducing capacity as directly available source of free sulfhydryl
groups and to elevated levels of intracellular cysteine, providing a
substrate for GSH synthesis (Atkuri et al., 2007). Another active
thiol compound is L-2-oxothiazolidine-4-carboxylate (OTC), a
lipophilic cysteine precursor that is converted intracellularly
to free cysteine via the oxo-L-prolinase reaction (Meister,
1991; Porta et al., 1991). Although many similar compounds
may also be effective, potential therapeutic interventions with
thiol antioxidants should be developed with caution, since
profound changes in thiol redox status could result in
adverse effects. These might include derangement of transport
signaling processes that are dependent on disulfide bonds in
membrane proteins, single-electron oxidation of thiols forming
thiyl radicals or a disequilibrium in the plasma thiol/disulfide
balance that is typically comprised of more oxidized thiols
under physiological circumstances (Kalyanaraman, 1995; Atkuri
et al., 2007). Nevertheless, future thiol-based therapy, which
has not been investigated yet, might be a promising strategy
to beneficially modulate antioxidant bioavailability, as long
as it is individually targeted to patients with pathological
ROS production and, accordingly, reduced concentrations of
plasma free thiols.
In the present study, we found CRP levels and BMI
to be inversely associated with albumin-adjusted plasma
free thiols. These results corroborate findings of a previous
study in which free thiol concentrations were associated
with clinical parameters in renal transplant recipients (Frenay
et al., 2016). Similarly to our study, BMI appeared to be
independently associated with plasma free thiol concentrations.
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Furthermore, this result is in agreement with another study
that demonstrated protein-adjusted free thiols to be associated
with a more favorable cardiovascular risk profile (Koning
et al., 2016). In CD, obesity, as represented by an elevated
BMI, has been associated with an increased risk of disease
development, possibly through its association with (intestinal)
inflammation (Khalili et al., 2015). Specifically for CD, it
has been suggested that visceral adipose tissue (VAT), rather
than total adiposity, is mainly affecting the risk of CD
disease progression and largely contributes to the systemic
inflammatory response (van der Sloot et al., 2017). In
contrast to previous studies, the significance of the inverse
relation between plasma free thiols and CRP levels was
lost in multivariable analyses. Nonetheless, we were able to
demonstrate significant inverse correlations between albumin-
adjusted plasma free thiols and an array of inflammatory
biomarkers, including the acute-phase reactants hsCRP, SAA,
and the pro-inflammatory cytokine IL-17A, and a non-
significant inverse correlation with VEGF. These data further
confirm that inflammation and oxidative stress are two
highly associated pathophysiological processes, represented by
strong (negative) correlations of (anti)oxidant substances with
higher concentrations of pro-inflammatory mediators in CD
(Biasi et al., 2013).
Interestingly, albumin-adjusted plasma free thiol concentra-
tions were most strikingly reduced in CD patients with
only colonic disease. Indeed, previous literature shows that
antioxidant capacity (as measured by enzymatic activity of SOD,
catalase, and GSH) is relatively low in the colonic mucosa,
already under physiological circumstances (Grisham et al., 1990).
Furthermore, a considerable amount of evidence points toward
increased mucosal ROS production in the inflamed colon that
significantly correlates with CD disease activity (Kruidenier
and Verspaget, 2002). Correspondingly, increased nitric oxide
(NO) concentrations, belonging to the reactive nitrogen species
(RNS), and being a major determinant of cellular redox status,
have been found in colonic biopsy specimens of CD patients,
including elevated expression of the NO-producing inducible
nitric oxide synthase (iNOS) enzyme in the inflamed colonic
mucosa (Boughton-Smith et al., 1993; Rachmilewitz et al., 1995;
Dijkstra et al., 1998).
A strength of the present study is the inclusion of a
healthy control group that enabled us to properly demonstrate
differences in plasma free thiol concentrations with the
CD study cohort. Furthermore, the study was sufficiently
powered to detect significant differences between two extensively
characterized cohorts of CD patients and healthy subjects.
Despite this, some study limitations have to be taken into
account. Most obviously, a greater sample size, including
patients with more active disease, would have allowed us
to more reliably establish associations between plasma free
thiols and recorded disease-specific parameters. Furthermore,
we were not able to examine plasma free thiols as potential
biomarker for disease exacerbations, since endoscopic data
close to the time of serum withdrawal were not available
for this patient cohort. Similarly, no serial assessments were
performed, which could have enabled us to examine plasma
free thiols in relation to response to therapy or as risk
factor for disease-related complications or hospitalization.
In addition, the current study focused specifically on CD,
but it would be interesting to study plasma free thiols
in ulcerative colitis (UC) and compare putative correlations
between both IBD entities.
In conclusion, we showed that albumin-adjusted plasma
free thiols are significantly reduced in CD when compared
to healthy subjects, especially in patients with colonic CD.
Furthermore, we demonstrated above-average plasma free thiols
to be associated with favorable outcome in CD, i.e., lower
BMI and lower levels of inflammatory biomarkers (hsCRP,
SAA, IL-17A, and VEGF). Future studies should focus on
the clinical utility of plasma free thiols in CD as overall
marker of systemic oxidative stress and aim to further unravel
associations with established disease parameters. This study
is of critical importance, since plasma free thiols form a
potential substrate for therapeutic intervention. Hence, future
antioxidant therapy might be a valuable strategy to ameliorate
disease status in CD.
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